Viewing nowPS Gabapentin Capsule 50 mg (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
Genew Pharm Co., Ltd.

MFDS item code 201906162 · Approved 2019.08.29 · Insurance code 698004160
Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset epileptic seizures
This medication is used in adults for the treatment of peripheral and central neuropathic pain. It is also used as an adjunct in the treatment of partial seizures in epilepsy patients, whether or not they have secondary generalized symptoms. Additionally, it helps alleviate symptoms of fibromyalgia. It is effective for treating significant pain related to the nervous system, seizures, and muscle pain.
This medication is administered orally, with or without food, as pregabalin in the total daily dose divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: As there are insufficient safety and efficacy data, use is not recommended. Adolescent patients aged 12-17 years: As there are insufficient safety and efficacy data, use is not recommended.
This drug may increase the risk of suicidal thoughts or behaviors, so it is essential to closely monitor mental health conditions such as depression or mood changes while taking this medication. Patients who are allergic to any of the ingredients in this drug or have specific hereditary lactose intolerance should not take it. Diabetic patients should be cautious as they may need to adjust their blood sugar control medications due to weight gain after taking this drug. If serious allergic reactions like angioedema occur, patients should immediately stop taking the medication and consult their healthcare provider. Elderly patients may have an increased risk of falls due to dizziness or drowsiness, especially during the initial phase of treatment. Blurry vision or changes in vision may occur, and patients should consult their doctors if these symptoms arise. Stopping this medication abruptly may result in withdrawal symptoms such as insomnia, headache, and anxiety, so dosage should be gradually reduced following a doctor's instructions. Patients with a history of substance abuse should use this medication cautiously as the risk of abuse may be higher. Patients with impaired kidney function may need dosage adjustments, so consultation with their healthcare provider is recommended. Patients with severe heart disease need to be cautious when taking this drug. Taking this drug with other CNS depressants or opioids may increase the risk of respiratory depression and should be approached with caution. Early in pregnancy, there may be a risk of congenital disabilities for the fetus, so pregnant women should avoid taking this drug or consult with their doctor. Nursing women should consider discontinuing breastfeeding or the medication itself since this drug may be excreted in breast milk, and they should discuss this with their healthcare provider. Drivers and operators of hazardous machinery should refrain from doing so until dizziness and drowsiness resolve. In case of overdose, patients should seek medical attention immediately for appropriate treatment, and blood dialysis may be required if necessary. This drug should be stored out of reach of children, and it is safest not to transfer it to another container. If severe rashes, swelling, difficulty breathing, or other symptoms occur while taking this medication, patients should stop taking it immediately and consult their healthcare provider.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best kept at room temperature between 15 and 30 degrees Celsius. Avoid storing it in excessively hot or cold places to help maintain its effectiveness.
A hard capsule with a dark blue upper part and a white lower part containing white powder.
30 capsules per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Hard capsule · Prescription medication
Genew Pharm Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.